Gene transfer: the challenge of regulated gene expression

Trends in Molecular Medicine

Volumn 14, Issue 9, 2008, Pages 410-418

  Guo, Z Sheng ^a   Li, Qiang ^a   Bartlett, David L ^a   Yang, James Y ^b   Fang, Bingliang ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b XIAMEN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CIS ACTING ELEMENT; DNA METHYLTRANSFERASE INHIBITOR; E1B PROTEIN; EARLY GROWTH RESPONSE FACTOR; EARLY GROWTH RESPONSE FACTOR 1; ELONGATION FACTOR 1ALPHA; GENDICINE; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY; ONCOLYTIC ADENOVIRUS; ONCORINE; PARVOVIRUS VECTOR; PHOSPHOGLYCERATE KINASE; PROTEIN P53; PROTEIN VP16; RAPAMYCIN; RESVERATROL; RETROVIRUS VECTOR; TNFERADE; TRANSCRIPTION FACTOR GAL4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTIFICIAL CHROMOSOME; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CYTOMEGALOVIRUS; DNA DAMAGE; DRUG POTENTIATION; ENHANCER REGION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE TRANSFER; GENETIC TRANSCRIPTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HYPERTHERMIA; HYPOXIA; IMMUNOTHERAPY; IONIZING RADIATION; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PROMOTER REGION; REVIEW; RNA INTERFERENCE; ROUS SARCOMA ONCOVIRUS; STEM CELL GENE THERAPY; TRANSCRIPTION REGULATION; VIRUS GENOME;

ANIMALS; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; HUMANS; PROMOTER REGIONS, GENETIC; STEM CELLS; TRANSCRIPTION, GENETIC;

EID: 50549093286     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.07.003     Document Type: Review

References (99)

1. Terazaki Y., et al. An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice. Hepatology 37 (2003) 155-163
2. Goverdhana S., et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 12 (2005) 189-211
3. Chen P., et al. Promoters influence the kinetics of transgene expression following adenovector gene delivery. J. Gene Med. 10 (2008) 123-131
4. Vilaboa N., and Voellmy R. Regulatable gene expression systems for gene therapy. Curr. Gene Ther. 6 (2006) 421-438
5. Matthaei K.I. Genetically manipulated mice: a powerful tool with unsuspected caveats. J. Physiol. 582 (2007) 481-488
6. Overbeek P.A., et al. Tissue-specific expression in transgenic mice of a fused gene containing RSV terminal sequences. Science 231 (1986) 1574-1577
7. Boulos S., et al. Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures. Brain Res. 1102 (2006) 27-38
8. Hong S., et al. Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol. Ther. 15 (2007) 1630-1639
9. Weber E.L., and Cannon P.M. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum. Gene Ther. 18 (2007) 849-860
10. Nakai M., et al. Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. Hum. Gene Ther. 18 (2007) 925-936
11. Curtin J.A., et al. Bidirectional promoter interference between two widely used internal heterologous promoters in a late-generation lentiviral construct. Gene Ther. 15 (2008) 384-390
12. McCart J.A., et al. Development of a melanoma-specific adenovirus. Mol. Ther. 6 (2002) 471-480
13. Bilsland A.E., et al. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res. 67 (2007) 1299-1307
14. Reboredo M., et al. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo. Gene Ther. 15 (2008) 277-288
15. Rohmer S., et al. Insulated hsp70B′ promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses. J. Gene Med. 10 (2008) 340-354
16. Guo Z.S., et al. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther. 3 (1996) 802-810
17. Kawabata K., et al. Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. Mol. Ther. 12 (2005) 547-554
18. Kim S., et al. Efficiency of the elongation factor-1α promoter in mammalian embryonic stem cells using lentiviral gene delivery systems. Stem Cells Dev. 16 (2007) 537-545
19. Al-Dosari M., et al. Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. Biochem. Biophys. Res. Commun. 339 (2006) 673-678
20. Lawinger P., et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat. Med. 6 (2000) 826-831
21. Halbert C.L., et al. High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. Hum. Gene Ther. 18 (2007) 344-354
22. Löser P., et al. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NF-κB. J. Virol. 72 (1998) 180-190
23. Brooks A.R., et al. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J. Gene Med. 6 (2004) 395-404
24. Xia X., et al. Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev. 16 (2007) 167-176
25. Yao S.Y., et al. Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications. Mol. Ther. 10 (2004) 27-36
26. Tashiro K., et al. Efficient adenovirus vector-mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation. J. Gene Med. 10 (2008) 498-507
27. Davis J.J., et al. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther. 13 (2006) 720-723
28. Gruh I., et al. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J. Gene Med. 10 (2008) 21-32
29. Jacobs F., et al. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther. 15 (2008) 594-603
30. Saukkonen K., and Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther. 4 (2004) 683-696
31. Rocha S. Gene regulation under low oxygen: holding your breath for transcription. Trends Biochem. Sci. 32 (2007) 389-397
32. Binley K., et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther. 6 (1999) 1721-1727
33. Jiang B., et al. Hypoxic response elements control expression of human vascular endothelial growth factor (165) genes transferred to ischemia myocardium in vivo and in vitro. J. Gene Med. 9 (2007) 788-796
34. Post D.E., et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 67 (2007) 6872-6881
35. Datta R., et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10149-10153
36. Park J.O., et al. Transcriptional control of viral gene therapy by cisplatin. J. Clin. Invest. 110 (2002) 403-410
37. Mezhir J.J., et al. Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 13 (2006) 1-6
38. Hallahan D.E., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1 (1995) 786-791
39. Bickenbach K.A., et al. Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy. Cancer Gene Ther. 15 (2008) 133-139
40. Senzer N., et al. TNFerade Biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor α gene: a phase I study in patients with solid tumors. J. Clin. Oncol. 22 (2004) 592-601
41. McLoughlin J.M., et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor α, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann. Surg. Oncol. 12 (2005) 825-830
42. Coulter J.A., et al. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther. 15 (2008) 495-503
43. McCarthy H.O., et al. p21(WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther. 14 (2007) 246-255
44. Greco O., et al. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer. Gene Ther. 13 (2006) 206-215
45. Siddiqui F., et al. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol. Cancer Ther. 6 (2007) 380-389
46. Plathow C., et al. Focal gene induction in the liver of rats by a heat-inducible promoter using focused ultrasound hyperthermia: preliminary results. Invest. Radiol. 40 (2005) 729-735
47. Walther W., et al. Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-α expression. Mol. Cancer Ther. 6 (2007) 236-243
48. Pankiewicz R., et al. Reversal of the silencing of tetracycline-controlled genes requires the coordinate action of distinctly acting transcription factors. J. Gene Med. 7 (2005) 117-132
49. Kramer B.P., et al. An engineered epigenetic transgene switch in mammalian cells. Nat. Biotechnol. 22 (2004) 867-870
50. Guo Z.S., et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 66 (2006) 1105-1113
51. Delgado-Enciso I., et al. A potent replicative Δ-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms. J. Gene Med. 9 (2007) 852-861
52. Sadowski I., et al. GAL4-VP16 is an unusually potent transcriptional activator. Nature 335 (1988) 563-564
53. Guo Z.S., and DePamphilis M.L. Specific transcription factors stimulate simian virus 40 and polyomavirus origins of DNA replication. Mol. Cell. Biol. 12 (1992) 2514-2524
54. Kagawa S., et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther. 7 (2000) 75-79
55. Koch P.E., et al. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol. Ther. 3 (2001) 278-283
56. Qiao J., et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther. 9 (2002) 168-175
57. Xie X., et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12 (2007) 52-65
58. Sato M., et al. Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging. Gene Ther. 15 (2008) 583-593
59. Toniatti C., et al. Gene therapy progress and prospects: transcription regulatory systems. Gene Ther. 11 (2004) 649-657
60. Agha-Mohammadi S., et al. Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J. Gene Med. 6 (2004) 817-828
61. Pluta K., et al. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J. Gene Med. 7 (2005) 803-817
62. Wang Y., et al. A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8180-8184
63. No D. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3346-3351
64. Rivera V.M., et al. A humanized system for pharmacologic control of gene expression. Nat. Med. 2 (1996) 1028-1032
65. Wilber A., et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells 25 (2007) 2919-2927
66. Ren X., et al. Human artificial chromosome vectors meet stem cells: new prospects for gene delivery. Stem Cell Rev. 2 (2006) 43-50
67. Kazuki Y., et al. Correction of a genetic defect in multipotent germline stem cells using a human artificial chromosome. Gene Ther. 15 (2008) 617-624
68. Adachi K., et al. Establishment of the gene-inducible system in primate embryonic stem cell lines. Stem Cells 24 (2006) 2566-2572
69. Vincent R., et al. Generation and characterization of novel tetracycline-inducible pancreatic transcription factor-expressing murine embryonic stem cell lines. Stem Cells Dev. 15 (2006) 953-962
70. Wang J., et al. Site-directed, virus-free, and inducible RNAi in embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20850-20855
71. Xia X., et al. In vitro- and in vivo-induced transgene expression in human embryonic stem cells and derivatives. Stem Cells 26 (2008) 525-533
72. Conrad C., et al. Genetically engineered stem cells for therapeutic gene delivery. Curr. Gene Ther. 7 (2007) 249-260
73. Daley G.Q., and Scadden D.T. Prospects for stem cell-based therapy. Cell 132 (2008) 544-548
74. Böcker, W. et al. Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. J. Cell. Mol. Med. (in press)
75. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16 (2005) 1016-1027
76. Yu W., and Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7 (2007) 141-148
77. Posner M., et al. Multi-center phase II/III randomized controlled clinical trial using TNFerade combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC). J. Clin. Oncol. 25 Suppl. (2007) 4518
78. Hardcastle J., et al. Oncolytic viruses driven by tumor-specific promoters. Curr. Cancer Drug Targets 7 (2007) 181-189
79. Guo Z.S., et al. Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785 (2008) 217-231
80. Abdul-Ghani R., et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther. 2 (2000) 539-544
81. Gu J., et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 60 (2000) 5359-5364
82. Koga S., et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther. 11 (2000) 1397-1406
83. Kim E., et al. Ad-mTERT-Δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 14 (2003) 1415-1428
84. Lanson Jr. N.A., et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 63 (2003) 7936-7941
85. Wirth T., et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 63 (2003) 3181-3188
86. Fujiwara T., et al. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr. Cancer Drug Targets 7 (2007) 191-201
87. Griffith C., et al. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Ther. 14 (2007) 985-993
88. Banerjee N.S., et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol. Cancer Ther. 3 (2004) 437-449
89. Kuroda T., et al. Effective treatment of tumors with strong β-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res. 66 (2006) 10127-10135
90. Fang J., et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23 (2005) 584-590
91. Fang J., et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol. Ther. 15 (2007) 1153-1159
92. Liu B.H., et al. GAL4-NF-κB fusion protein augments transgene expression from neuronal promoters in the rat brain. Mol. Ther. 14 (2006) 872-882
93. Liu B.H., et al. Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain. J. Gene Med. 10 (2008) 583-592
94. Vogel R., et al. Lentiviral vectors mediate nonimmunosuppressive rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of transcription and exocytosis. Hum. Gene Ther. 19 (2008) 167-178
95. Le Guiner C., et al. Immune responses to gene product of inducible promoters. Curr. Gene Ther. 7 (2007) 334-346
96. Lowenstein P.R., et al. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr. Gene Ther. 7 (2007) 347-360
97. Follenzi A., et al. Immune responses to lentiviral vectors. Curr. Gene Ther. 7 (2007) 306-315
98. Yeo Z.X., et al. Sequential logic model deciphers dynamic transcriptional control of gene expressions. PLoS ONE 2 (2007) e776
99. Wang W.D., et al. Construction of an artificial intercellular communication network using the nitric oxide signaling elements in mammalian cells. Exp. Cell Res. 314 (2008) 699-706